Cellular and molecular mechanisms underlying IL-12-induced tumor regression

Annals of the New York Academy of Sciences

Volumn 795, Issue , 1996, Pages 294-309

  Fujiwara, Hiromi ^a   Clark, Steven C ^b   Hamaoka, Toshiyuki ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; MESSENGER RNA; MONOCLONAL ANTIBODY; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RECOMBINANT INTERLEUKIN 12; SPHINGOMYELIN;

ANTINEOPLASTIC ACTIVITY; CELL MIGRATION; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; FIBROSARCOMA; GRAFT REJECTION; HOST RESISTANCE; IMMUNE RESPONSE; INFLAMMATION; INTRAPERITONEAL DRUG ADMINISTRATION; METASTASIS; MONONUCLEAR CELL; NATURAL KILLER CELL; NONHUMAN; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR REGRESSION; TUMOR VOLUME;

EID: 0030473466     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1996.tb52679.x     Document Type: Conference Paper

References (47)

1. KOBAYASHI, M., L. FITZ, M. RYAN, R. M. HEWICK, S. C. CLARK, S. CHAN, R. LOUDON, F. SHERMAN, B. PERUSSIA & G. TRINCHIERI. 1989. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biological effects on human lymphocytes. J. Exp. Med. 170: 827-845.
2. STERN, A. S., F. J. PODLASKI, J. D. HULMES, Y. C. E. PAN, P. M. QUINN, A. G. WOLITZKY, P. C. FAMILLETTI, D. L. STREMLO, T. TRUITT, R. CHIZZONITE & M. K. GATELY. 1990. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc. Natl. Acad. Sci. USA 87: 6808-6812.
3. ROBERTSON, M. J., R. J. SOIFFER, S. F. WOLF, T. J. MANLEY, C. DONAHUE, D. YOUNG, S. H. HERRMANN & J. RITZ. 1992. Responses of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): Cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J. Exp. Med. 175: 779-788.
4. GATELY, M. K., B. B. DESAI, A. G. WOLITZKY, P. M. QUINN, C. M. DWYER, F. J. PODLASKI, P. C. FAMILLETTI, F. SINIGAGLIA, R. CHIZZONITE, U. GUBLER & A. S. STERN. 1991. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J. Immunol. 147:874-882.
5. PERUSSIA, B., S. H. CHAN, A. D'ANDREA, K. Tsuii, D. SANTOLI, M. POSPISIL, D. YOUNG, S. F. WOLF & G. TRINCHIERI. 1992. Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-a +, TCR-y 8+ T lymphocytes and NK cells. J. Immunol. 149: 3495-3502.
6. CHAN, S. H., B. PERUSSIA, J. W. GUPTA, M. KOBAYASHI, M. POSPISIL, H. A. YOUNG, S. F. WOLF, D. YOUNG, S. C. CLARK & G. TRINCHIERI. 1991. Induction of interferon y production by natural killer cell stimulatory factor: Characterization of the responding cells and synergy with other inducers. J. Exp. Med. 173: 869-879.
7. MANETTI, R., P. PARRONCHI, M. G. GIUDIZI, M. P. PICCINNI, E. MAGGI, G. TRINCHIERI & S. ROMAGNANI. 1993. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 [Thl]-specific immune responses and inhibits the development of IL-4-producing Th cells. J. Exp. Med. 177: 1199-1204.
8. TRINCHIERI, G. 1993. Interleukin-12 and its role in the generation of TH1 cells. Immunol. Today 14: 335-338.
9. BRUNDA, M. J., L. LUISTRO, R. R. WARRIER, R. B. WRIGHT, B. R. HUBBARD, M. MURPHY, S. F. WOLF & M. K. GATELY. 1993. Antitumor and antimetastatic activity of interleukin-12 against murine tumors. J. Exp. Med. 178: 1223-1230.
10. NASTALA, C. L., H. D. EDINOTON, T. G. McKiNNEY, H. TAMARA, M. A. NALESNIK, M. J. BRUNDA, M. K. GATELY, S. F. WOLF, R. D. SCHREIBER, W. T. STEWART, J. STORKUS & M. T. LOTZE. 1994. Recombinant interleukin-12 (IL-12) administration induces tumor regression in association with interferon-y production. J. Immunol. 153: 1697-1706.
11. Zou,J. P., N. YAMAMOTO, T. FUJII, H.TAKENAKA, M. KOBAYASHI, S. H. HERRMANN, S. F. WOLF, H. FUJIWARA & T. HAMAOKA. 1995. Systemic administration of rIL-12 induces complete tumor regression and protective immunity: Response is correlated with a striking reversal of suppressed interferon-y production by anti-tumor T cells. Intl. Immunol. 7: 1135-1145.
12. NOGUCHI, Y., E. C. RICHARDS, Y. T. CHEN & L. J. OLD. 1995. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc. Natl. Acad. Sci. USA 92: 2219-2223.
13. VERBIK, D. J., W. W. STINSON, M. J. BRUNDA, A. KESSINGER & S. S. JOSHI, 1995. Therapeutic effects of in vivo administration of interleukin-12 against residual lymphoma. Proc. Am. Assoc. Cancer Res. 36: 480.
14. Yu, W. G., N. YAMAMOTO, H. TAKENAKA, X. G. TAI, J. P. Zou, M. OGAWA, T. TSUTSUI, R. WlJESURIYA, R. YOSHIDA, S. HERRMANN, H. FUJIWARA & T. HAMAOKA. 1996. Molecular mechanisms underlying IFN-γ-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12. Int. Immunol. In press.
15. Mu, J., J. P. Zou, N. YAMAMOTO, T. TSUTSUI, X. G. TAI, M. KOBAYASHI, S. HERRMANN, H. FUJIWARA & T. HAMAOKA. 1996. Administration of rIL-12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res. 55: 4404-4408.
16. MARTINOTTI, A., A. STOPPACCIARO, M. VAGLIANI, C. MELANI, F. SPREAFICO, M. WYSOCKA, G. PARMIANI, G. TRINCHIERI & M. P. COLOMBO. 1995. CD4 T cells inhibit in vivo the CDS-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur. J. Immunol. 25: 137-146.
17. BRUNDA, M. J., L. LUISTRO, J. A. HENDRZAK, M. FOUNTOULAKIS, G. GAROTTA & M. K. GATELY. 1995. Role of interferon-γ in mediating the antitumor efficacy of interleukin-12. J. Immunother. 17: 71-77.
18. FUJIWARA, H., J. P. Zou, S. HERRMANN & T. HAMAOKA. 1995. A sequence of cellular and molecular events involved in IL-12-induced tumor regression. Res. Jmmunol. 146: 636-644.
19. KlTAGAWA, S., H. IWATA, S. SATO, J. SHIMIZU, T. HAMAOKA & H. FUJIWARA. 1991. Heterogeneous graft rejection pathways in class I major histocompatibility complexdisparate combinations and their differential susceptibility to immunomodulation induced by intravenous presensitization with relevant alloantigens. J. Exp. Med. 174:571-581.
20. + cells mediate skin graft rejection. J. Exp. Med. 153: 1044-1057.
21. +2- lymphocytes. J. Exp. Med. 154: 952-963.
22. - T cell-mediated tumor-eradicating mechanism in vivo. BioEssays 4: 19-23.
23. CHEN, L. K., B. TOURVEILLE, G. F. BURNS, F. H. BACH, D. MATIEU-MAHUL, M. SASPORTES & A. BENSUSSAN. 1986. Interferon: A cytotoxic T-lymphocyte differentiation signal. Eur. J. Immunol. 16: 767-770.
24. MARASKOVSKY, E., W. F. CHEN & K. SHORTMAN. 1989. IL-2 and IFN-γ are two necessary lymphokines in the development of cytotoxic T-cells. J. Immunol. 143: 1210-1214.
25. TOMURA, M., M. MURACHI, X. G. TAI, K. TOYO-OKA, I. NAKATANI & H. FUJIWARA. 1996. Downregulation of allograft responses by selective modulation of IFN-y but not of IL-2 production or function. Submitted.
26. BALKWILL, F. R. & F. BURKE. 1989. The cytokine network. Immunol. Today 10: 299-304.
27. XIE Q. W., H. J. CHO, J. CALACAY, R. A. MUMFORD, K. M. SWIDEREK, T. D. LEE, A. DING, T. TROSO & C. NATHAN. 1992. Cloning and characterization of inducible nitric oxide synthase from mouse macrophages. Science (Washington, DC). 256: 225-228.
28. NATHAN, C. 1992. Nitric oxide as a secretory product of mammalian cells. FASEB J. 6: 3051-3064.
29. NATHAN, C. F. & J. B. HIBBS, JR. 1991. Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr. Opin. Immunol. 3: 65-70.
30. MONCADA, S., R. M. J. PALMER & E. A. HIGGS. 1991. Nitric oxide: Physiology, pathophysiology and pharmacology. Pharmacol. Rev. 43: 109-142.
31. HIBBS, J. B., R. R. TAINTOR, H. A. CHAPMAN & J. B. WEINBERG. 1977. Macrophage tumor killing: Influence of the local environment. Science 197: 279-282.
32. STUEHR, D. J. & C. F. NATHAN. 1989. Nitric oxide: A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J. Exp. Med. 169: 1543-1555.
33. DING, A. H., C. F. NATHAN & D. J. STUEHR. 1988. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. Comparison of activating cytokines and evidence for independent production. J. Immunol. 141: 2407-2412.
34. GELLER, D. A., A. K. NUSSLER, M. DISILVIO, C. J. LOWENSTEIN, R. A. SHAPIRO, S. C. WANG, R. L. SIMMONS & T. R. BILLIAR. 1993. Cytokines, endotoxin, and glucocorticoids regulate the expression of inducible nitric oxide synthase in hepatocytes. Proc. Natl. Acad. Sci. USA 90: 522-526.
35. ASANO, K., C. B. E. CHEE, B. GASTON, C. M. LILLY, C. GERARD, J. M. DRAZEN & J. S. STAMLER. 1994. Constitutive and inducible nitric oxide synthase gene expression, regulation, and activity in human lung epithelial cells. Proc. Natl. Acad. Sci. USA 91: 10089-10093.
36. SHIMIZU, T., S. NOMIYAMA, F. HIRATA & O. HAYAISHI. 1978. Indoleamine 2,3dioxygenase. Purification and some properties. J. Biol. Chem. 253: 4700-4706.
37. YOSHIDA, R., J. IMANISHI, T. OKU-KISHIDA & O. HAYAISHI. 1981. Induction of pulmonary indoleamine 2,3-dioxygenase by Interferon. Proc. Natl. Acad. Sci. USA 78: 129-132.
38. OZAKI, Y., M. P. EDELSTEIN & D. S. DUCH. 1988. Induction of indoleamine 2,3dioxygenase: A mechanism of the antitumor activity of interferon-y. Proc. Natl. Acad. Sci. USA 85: 1242-1246.
39. BURKE, F., R. G. KNOWLES, N. EAST & F. R. BALKWILL. 1995. The role of indoleamine 2,3-dioxygenase in the anti-tumor activity of human interferon-y in vivo. Intl. J. Cancer 60: 115-122. t
40. HANNUN, Y. A. 1994. The sphingomyelin cycle and the second messenger function of ceramide. J. Biol. Chem. 269: 3125-3128.
41. GOMEZ-MUNOZ, A., A. MARTIN, L. O'BRIEN & D. N. BRINDLEY. 1994. Cell-permeable ceramides inhibit the stimulation of DNA synthesis and phospholipase D activity by phosphatidate and lysophosphatidate in rat fibroblasts. J. Biol. Chem. 269: 8937-8943.
42. JARVIS, W. D., R. N. KOLESNICK, F. A. FORNARI, R. S. TRAYLOR, D. A. GEWIRTZ & S. GRANT. 1994. Induction of apoptotic DNA damage and cell death by activation of the sphingomyelin pathway. Proc. Natl. Acad. Sci. USA 91: 73-77.
43. KIM, M. Y., C. LINARDIC, L. OBEID & Y. HANNUN. 1991. Identification of sphingomyelin turnover as an effector mechanism for the action of tumor necrosis factor a and y-interferon: Specific role in cell differentiation. J. Biol. Chem. 266: 484-489.
44. OBEID, L. M., C. M. LINARDIC, L. A. KAROLAK & Y. A. HANNUN. 1993. Programmed cell death induced by ceramide. Science (Washington, DC) 259: 1769-1771.
45. MATHIAS, S., A. YOUNES, C. C. KAN, I. ORLOW, C. JOSEPH & R. N. KOLESNICK. 1993. Activation of the sphingomyelin pathway in intact EL4 cells and in a cell-free system by IL-1/3. Science (Washington, DC) 259: 519-522.
46. WALLACH, D., M. FELLOUS & M. REVEL. 1982. Preferential effect of interferon-y on the synthesis of HLA antigens and their mRNAs in human cells. Nature 299:833-836.
47. CELADA, A. & R. A. MAKI. 1991. IFN-y induces the expression of the genes for MHC class II I-A/3 and tumor necrosis factor through a protein kinase C-independent pathway. J. Immunol. 146: 114-120.